Drug Delivery Technology Development in Canada

Message from the Guest Editors

Canada continues to have a rich history of ground-breaking research in Drug delivery within academic institutions, pharmaceutical industry and the biotechnology community. Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. Over the past 25 years numerous Canadian-based biotechnology companies have been formed from the inventions conceived and developed within academic institutions that have led to the development of important drug delivery products that have enhanced the landscape of drug therapy in the treatment of cancer to infectious diseases. This special issue serves to highlight and capture the contemporary progress of drug delivery within the prevailing Canadian context. We invite articles on all aspects of drug delivery sciences from pre-clinical formulation development to human clinical trials that bring to light the world-class research currently undertaken in Canada for this special issue.
Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews. Citations available in PubMed, full-text archived in PubMed Central. Covered by Scopus: papers published between 2014 and 2016 have been cited 3.68 times, on average, in 2017 (CiteScore 2017).

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in the first half of 2018).

Contact us

Pharmaceutics
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
@MDPlpharma